|Mr. Peter Jonathan Butterfield||CEO & Exec. Director||328.99k||N/A||1976|
|Mr. Andrew Timothy Franklin||CFO & Exec. Director||241.9k||N/A||1966|
|Mr. Stephen Kidner||Chief Scientific & Operations Officer||N/A||N/A||N/A|
|Mr. Daniel Thomas||Chief Corp. Devel. Officer||N/A||N/A||N/A|
|Ms. Janice Timberlake||Chief HR Officer||N/A||N/A||N/A|
Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally. The company acquires, markets, and sells pharmaceutical and healthcare products. It owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The company also provides prescription only medicines, over the counter medications, cosmetics, and nutritional supplements, as well as medical devices. In addition, it offers products in various therapeutic areas, including acquired healthcare, cardiovascular, central nervous system, child health, consumer health, dermatology, endocrinology, gastroenterology, obstetrics and gynecology, oral health, oncology, stoma care, toxicology, travel health, urology, vitamins and minerals, and others. Further, the company provides its products under the Kelo-Cote, Nizoral, MacuShield, Vamousse, Xonvea, Flamma Franchise, Aloclair, Hydromol, Forceval, Haemopressin, Optiflo, Oxyplastine, Ashton & Parsons, and Ametop brand names. The company distributes its products through wholesalers, retail pharmacies, hospitals, and network of distributors. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
Alliance Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.